Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2024-01-23 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
百济神州有限公司关于独立非执行董事辞任、委任独立非执行董事及董事会专门委员会成员变动的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding changes in the company's board of directors, specifically the resignation of an independent non-executive director and the appointment of a new independent non-executive director, along with changes in board committee memberships. It includes details about the new director's background, compensation, and terms of appointment. There is no financial data, earnings information, or report publication mentioned. The content clearly fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2024-01-23 Chinese
百济神州有限公司关于签订顾问协议暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the signing of a consultancy agreement and related party transaction involving a former independent non-executive director, Thomas Malley. It details the terms of the agreement, the background of the individual, shareholding information, and the board's approval process. There are no financial statements, quarterly or annual results, or audit opinions presented. The document is regulatory in nature, disclosing a related party transaction and corporate governance matters. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a report publication announcement since it contains substantive content rather than just a notice. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories. The document length is 4755 characters, which is substantive enough to be a full announcement rather than a brief notice.
2024-01-23 Chinese
中国国际金融股份有限公司、高盛（中国）证券有限责任公司关于百济神州有限公司签订顾问协议暨关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion and verification report from joint sponsors (China International Capital Corporation and Goldman Sachs China) regarding a related-party transaction involving a consulting agreement with a former independent non-executive director of the company, BeiGene Ltd. It discusses the background, terms, pricing, necessity, and approval procedures of the related-party transaction. The document references regulatory rules from the Shanghai Stock Exchange and internal company policies. It is not a financial report, earnings release, or management discussion, but rather a formal regulatory compliance and audit opinion on a specific transaction. This fits the category of Audit Report / Information (AR), as it is a standalone audit/verification report on a related-party transaction, not a full annual report or other category. Q1 2024
2024-01-23 Chinese
港股公告：授出购股权及受限制股份单位
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the grant of share options and restricted share units under the company's 2016 Option and Incentive Plan. It includes specifics such as grant dates, number of shares, exercise prices, vesting schedules, and the rationale behind the grants. The document references compliance with listing rules and is issued by the company's board remuneration committee. It is not a full financial report, earnings release, or management discussion, nor is it a proxy statement or voting result. It is a regulatory announcement about share-based compensation awards to employees and a service provider. Given the nature of the content and the reference to listing rules sections 17.06A, 17.06B, and 17.06C, this fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories. The document length is under 5,000 characters, but it contains substantive information about the share awards rather than just announcing a report publication, so it is not an RPA. Therefore, the classification is RNS with high confidence.
2024-01-05 Chinese
港股公告：证券变动月报表
Share Issue/Capital Change Classification · 95% confidence The document is a monthly securities movement report for a listed issuer and its Hong Kong Depositary Receipts, detailing changes in registered and issued share capital, share options, and other share-related agreements for the month ending December 31, 2023. It is addressed to the Hong Kong Stock Exchange and includes confirmations regarding compliance with listing rules and issuance approvals. The document is structured as a regulatory monthly report on share capital changes, not a financial report, earnings release, or management discussion. It does not contain financial statements or earnings data but focuses on share issuance and capital changes. This matches the definition of a Share Issue/Capital Change (SHA) filing, which covers announcements regarding new share issues or capital changes. The document length is about 4764 characters, sufficient to be the report itself rather than a brief announcement. Therefore, the correct classification is SHA with high confidence.
2024-01-05 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 100% confidence The document is a detailed disclosure report about changes in issued share capital and/or share repurchases by the company, including specific dates, share quantities, prices, and compliance with Hong Kong Stock Exchange listing rules (Main Board and GEM). It includes sections on share issuance under share award plans, share option exercises, and confirmations of board authorization. The document references specific listing rule sections (e.g., 13.25A, 17.27A) that require disclosure of share capital changes. The document is not a full financial report, earnings release, or management discussion, but a regulatory disclosure about share capital changes. It is not a short announcement but a substantive report with detailed data on share issuance and repurchases. This fits the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues, stock splits, or other capital changes.
2024-01-02 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.